Lentiviral Minigene Vaccine Uses, Dosage, Side Effects and more
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
| Trade Name | Lentiviral Minigene Vaccine |
| Generic | LV-SMENP Vaccine |
| LV-SMENP Vaccine Other Names | Covid-19 Synthetic Minigene Vaccine, Lentiviral Minigene Vaccine, LV-SMENP |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
